Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2017		Jul. 31, 2016	Jul. 31, 2015
OPERATING ACTIVITIES
Net income	$ 9,641		$ 25,358	$ 86,115
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	21,704		20,535	18,418
Deferred income taxes	(2,329)		3,809	5,877
Provision for doubtful accounts receivable	686	[1]	1,519	97
Gain on sale of interest in Fabrix Systems Ltd.			(1,086)	(76,864)
Gain on sale of member interest in Visa Europe Ltd.			(7,476)
Net realized (gain) loss from marketable securities	(323)		(543)	54
Interest in the equity of investments	(356)		362	(1,699)
Stock-based compensation	3,740		2,680	5,185
Change in assets and liabilities:
Restricted cash and cash equivalents	(17,702)		(22,548)	(28,286)
Trade accounts receivable	(17,972)		616	640
Prepaid expenses, other current assets and other assets	(4,856)		8,372	2,122
Trade accounts payable, accrued expenses, other current liabilities and other liabilities	17,344		(10,099)	(4,125)
Customer deposits	18,980		25,344	25,939
Deferred revenue	(9,543)		2,211	(2,939)
Net cash provided by operating activities	19,014		49,054	30,534
INVESTING ACTIVITIES
Capital expenditures	(22,949)		(18,370)	(28,556)
Payment for acquisition, net of cash acquired	(1,827)
Proceeds from sale of interest in Fabrix Systems Ltd., net of cash and cash equivalents sold			9,557	59,678
Proceeds from sale of member interest in Visa Europe Ltd			5,597
Cash used for purchase of investments	(9,438)		(2,002)	(125)
Proceeds from sales and redemptions of investments	15		634	119
Purchases of marketable securities	(53,402)		(46,909)	(52,360)
Proceeds from maturities and sales of marketable securities	47,996		35,011	24,126
Net cash (used in) provided by investing activities	(39,605)		(16,482)	2,882
FINANCING ACTIVITIES
Dividends paid	(17,874)		(17,358)	(47,594)
Distributions to noncontrolling interests	(1,482)		(1,834)	(2,050)
Sale of Class B common stock to Howard S. Jonas	24,930
Proceeds from sale of interest and rights in Rafael Pharmaceuticals, Inc. to Howard S. Jonas	1,000
Proceeds from sale of member interests in CS Pharma Holdings, LLC	1,250		8,750
Cash of Zedge deconsolidated as a result of spin-off			(6,381)
Proceeds from sale of Zedge equity prior to the spin-off			374
Proceeds from exercise of stock options	836			3,424
Repayments of borrowings including revolving credit loan payable			(6,353)	(13,271)
Purchase of Class B common stock from Howard S. Jonas				(7,500)
Repurchases of Class B common stock	(1,838)		(4,773)	(3,202)
Net cash provided by (used in) financing activities	6,822		(27,575)	(70,193)
Effect of exchange rate changes on cash and cash equivalents	292		(5,821)	(6,685)
Net decrease in cash and cash equivalents	(13,477)		(824)	(43,462)
Cash and cash equivalents at beginning of year	109,537		110,361	153,823
Cash and cash equivalents at end of year, including $5,716, $5,536 and $571 held for sale at July 31, 2017, 2016 and 2015, respectively (see Note 3)	96,060		109,537	110,361
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Cash payments made for interest	1,209		1,205	745
Cash payments made for income taxes	576		779	320
SUPPLEMENTAL SCHEDULE OF NON-CASH FINANCING AND INVESTING ACTIVITIES
Reclassification of liability for member interests in CS Pharma Holdings, LLC	8,750
Net assets excluding cash and cash equivalents of Zedge deconsolidated as a result of spin-off			(4,681)
Shares of Visa Inc. Series C preferred stock received from sale of member interest in Visa Europe Ltd.			1,580
Net liabilities excluding cash and cash equivalents of Fabrix Systems Ltd. sold				$ 14,333

[1] Includes allowance for doubtful accounts of $2,550 and $861 held for sale at July 31, 2017 and 2016, respectively (see Note 3)